Business Context and Reporting Period
Company: Moderna, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 11, 2020
Event: Entry into a Material Definitive Agreement with the U.S. Department of Defense (DoD) and Biomedical Advanced Research and Development Authority (BARDA) under Operation Warp Speed.
Key Financial Metrics and Agreement Terms
This filing details a specific supply agreement rather than general financial performance metrics (revenue, profit, cash flow) for a reporting period.
- Initial Commitment: $1.225 billion for the manufacturing and delivery of 100 million doses of mRNA-1273.
- Performance Bonus: Up to $300 million additional payment upon acceptance of initial doses, contingent on FDA Emergency Use Authorization (EUA) or Biologics License Application (BLA) approval by January 31, 2021.
- Total Committed Funding: $2.480 billion (inclusive of a prior $955 million BARDA award).
- Production Milestone Payment: Approximately $600 million payable upon presentation of production documentation, expected prior to approval or delivery.
- Option Value: Four separate options for the U.S. Government to purchase an additional 100 million doses each. Each option, if exercised, is valued at $1.65 billion.
- Contract Duration: Base period of nine months; extendable to 20 months if all options are exercised.
Material Changes and Unusual Items
The primary material change is the execution of the U.S. Supply Agreement, significantly increasing the Company's potential revenue from the U.S. Government for its investigational COVID-19 vaccine candidate.
- Termination Clauses: The U.S. Government retains the right to terminate the agreement if deemed in its interest. In the event of termination, payment amounts are subject to agreement.
- Contingency for Bankruptcy or Termination: If Moderna terminates manufacture/sale or files for bankruptcy protection prior to fulfilling supply commitments, the Company must provide the U.S. Government with a royalty-free, irrevocable license to Moderna's IP, necessary regulatory filings, and outstanding deliverables to enable third-party manufacturing exclusively for the U.S. Government.
- Novation: The agreement may be novated to another wholly-owned subsidiary of the Company.
Guidance, Outlook, and Risks
Outlook: The agreement supports the Company's timeline for manufacturing and delivery, with a base performance period of nine months. The potential for up to $2.480 billion in committed funding and significant option value ($6.6 billion total potential if all options exercised) underscores the strategic importance of this partnership.
Risks and Contingencies:
- Regulatory Approval: The $300 million bonus and the exercise of purchase options are contingent upon FDA EUA or BLA approval.
- Government Discretion: The U.S. Government has sole discretion to exercise the four additional purchase options.
- IP Transfer Risk: Specific bankruptcy or termination scenarios trigger a mandatory transfer of IP rights and manufacturing capabilities to the U.S. Government.
Investor Verification Checklist
- Verify the exact terms of the $300 million performance bonus and the specific FDA approval deadlines (January 31, 2021).
- Review the full U.S. Supply Agreement (to be filed as an exhibit to the Q3 2020 Form 10-Q) for detailed termination and payment conditions.
- Assess the Company's manufacturing capacity to meet the 100 million dose initial commitment within the nine-month base period.
- Monitor the status of the prior $955 million BARDA award and its integration with the new agreement.
- Confirm the timeline for the $600 million production documentation payment.
